Specificity of 89 Zr-trastuzumab for HER2-positive tumors sorted by
relevance

Admin10.08.2021

Specificity of 89 Zr-trastuzumab for HER2-positive tumors

406
Admin28.09.2021

Specificity of 89 Zr-trastuzumab for HER2-positive tumors

8102
Admin18.07.2021

Site-specific 89 Zr-DFO-trastuzumab PET/CT imaging in PDX

106
Admin27.09.2021

Specificity of 89Zr-trastuzumab for HER2-positive tumors

7604
Admin24.07.2021

Site-specific 89 Zr-DFO-trastuzumab PET/CT imaging in PDX

8600
Admin19.07.2021

[ 89 Zr]trastuzumab PET scan of a patient with HER2

86010
Admin17.09.2021

Specificity of 89Zr-trastuzumab for HER2-positive tumors

9102
Admin05.08.2021

89 Zr-trastuzumab-PET showing uptake in a brain metastasis

8709
Admin01.08.2021

Monitoring Afatinib Treatment in HER2-Positive Gastric

9403
Admin21.08.2021

Radiochemistry and in vitro evaluation of 89 Zr-DFO

7704
Admin06.10.2021

Site-specific 89 Zr-DFO-trastuzumab PET/CT imaging in PDX

Admin02.09.2021

(PDF) N-Acetylcysteine breaks resistance to trastuzumab

3706
Admin30.09.2021

Role of HER2 in Gastric Cancers | Abdominal Key

2908
Admin12.09.2021

Specificity of 89Zr-trastuzumab for HER2-positive tumors

8203
Admin06.10.2021

Detection of HER2-Positive Metastases in Patients with

9500
Admin31.07.2021

(PDF) Monitoring afatinib treatment in HER2-positive

4708
Admin06.08.2021

Monitoring Afatinib Treatment in HER2-Positive Gastric

9609
Admin28.09.2021

Correlative analysis between 89 Zr-trastuzumab and 18 F

2002
Admin13.09.2021

Detection of HER2-Positive Metastases in Patients with

6508
Admin27.07.2021

Zirconium-89 Labeled Antibodies: A New Tool for Molecular

Admin01.08.2021

(PDF) Monitoring afatinib treatment in HER2-positive

7303